Chemed (CHE) Misses Q3 EPS by 3c, Offers Guidance

Chemed (NYSE: CHE) reported Q3 EPS of $1.48, $0.03 worse than the analyst estimate of $1.51. Revenue for the quarter came in at $358.4 million versus the consensus estimate of $360 million.

Chemed sees FY2014 EPS of $6.00-$6.05, versus the consensus of $5.95.

For earnings history and earnings-related data on Chemed (CHE) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• Scinai posts H1 2026 results with wider operating loss, net gain
• Needham Reiterates Buy Rating on Veeva Systems (VEEV)